drugset / Trial / NCT01483846

Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers

NCT01483846

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1b study involving multiple oral doses of AV-101 in healthy male and female subjects. The safety, pharmacokinetics, and antihyperalgesic effect of AV-101 on capsaicin-induced hyperalgesia will be assessed.

Timeline

Start
2011-12
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AV-101 Small molecule 360 mg Oral
Subject AV-101 Small molecule 1080 mg Oral
Subject AV-101 Small molecule 1440 mg Oral

Indications